Alger Health Sciences Fund Class Z (AHSZX)
| Fund Assets | 64.41M |
| Expense Ratio | 0.77% |
| Min. Investment | $500,000 |
| Turnover | 289.28% |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Dividend Growth | n/a |
| Payout Frequency | n/a |
| Ex-Dividend Date | n/a |
| Previous Close | 24.26 |
| YTD Return | 3.15% |
| 1-Year Return | 18.40% |
| 5-Year Return | -11.75% |
| 52-Week Low | 17.72 |
| 52-Week High | 24.44 |
| Beta (5Y) | n/a |
| Holdings | 53 |
| Inception Date | May 28, 2015 |
About AHSZX
Alger Health Sciences Fund Class Z is an actively managed mutual fund focused on the health sciences sector. The fund seeks long-term capital appreciation by investing at least 80% of its net assets in equity securities of companies operating within the healthcare industry, including drug manufacturers, biotechnology firms, medical device companies, and related healthcare services. By emphasizing growth stocks across a range of market capitalizations, the fund aims to capture opportunities from innovation and advances in medical technology and healthcare delivery. Alger Health Sciences Fund Class Z leverages fundamental research to identify companies with strong growth potential and has maintained a cost structure that is competitive within its peer group. As a sector equity fund, it plays a specialized role in the financial market, allowing investors to target exposure to the dynamic and evolving healthcare industry, which is often influenced by trends in medical breakthroughs, demographics, and regulatory changes.
Performance
AHSZX had a total return of 18.40% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.84%.
Top 10 Holdings
40.56% of assets| Name | Symbol | Weight |
|---|---|---|
| Welltower Inc. | WELL | 4.60% |
| Eli Lilly and Company | LLY | 4.40% |
| Cardinal Health, Inc. | CAH | 4.39% |
| Biogen Inc. | BIIB | 4.08% |
| Impulse Dynamics Ireland Series F-3 | n/a | 4.01% |
| CVS Health Corporation | CVS | 3.96% |
| AstraZeneca PLC | AZN | 3.92% |
| McKesson Corporation | MCK | 3.91% |
| AbbVie Inc. | ABBV | 3.68% |
| Forte Biosciences, Inc. | FBRX | 3.61% |